Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study

IF 4.4 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2026-01-01 Epub Date: 2025-12-27 DOI:10.1016/j.dsx.2025.103369

Shuo Li , Yifan Zhang , Xuan Liu , Yun Chai, Hongwei Jia, Hua Shu, Yuxin Fan, Li Ding, Ming Liu

{"title":"Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study","authors":"Shuo Li , Yifan Zhang , Xuan Liu , Yun Chai, Hongwei Jia, Hua Shu, Yuxin Fan, Li Ding, Ming Liu","doi":"10.1016/j.dsx.2025.103369","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to evaluate the safety and efficacy of finerenone in the treatment of primary aldosteronism (PA).</div></div><div><h3>Methods</h3><div>A total of 15 patients with PA were enrolled. The primary endpoint was the proportion of patients achieving normal serum potassium levels without potassium supplementation at the 4-week (4W) follow-up. Secondary endpoints included changes in serum potassium, 24-h urinary potassium, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Serum creatinine, estimated glomerular filtration rate (eGFR), and hyperkalemia incidence were also assessed during follow-ups.</div></div><div><h3>Results</h3><div>At baseline, all patients had hypokalemia (serum potassium <3.5 mmol/L). At 4W, 47 % (7/15) of patients achieved normal serum potassium without supplementation. Serum potassium levels significantly increased at the 2W, 4W, and 8W follow-ups compared to baseline (all p < 0.05). SBP significantly decreased at the 4W and 8W follow-ups (all p < 0.05), while DBP showed no significant changes. Increases in serum creatinine and decreases in eGFR were observed, particularly in patients with PA and chronic kidney disease (CKD), although these changes were not statistically significant. No instances of hyperkalemia or unexpected safety concerns were reported.</div></div><div><h3>Conclusion</h3><div>Finerenone effectively increased serum potassium levels and reduced SBP in PA, demonstrating its potential as a promising treatment option.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 1","pages":"Article 103369"},"PeriodicalIF":4.4000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1871402125001869","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

This study aimed to evaluate the safety and efficacy of finerenone in the treatment of primary aldosteronism (PA).

Methods

A total of 15 patients with PA were enrolled. The primary endpoint was the proportion of patients achieving normal serum potassium levels without potassium supplementation at the 4-week (4W) follow-up. Secondary endpoints included changes in serum potassium, 24-h urinary potassium, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Serum creatinine, estimated glomerular filtration rate (eGFR), and hyperkalemia incidence were also assessed during follow-ups.

Results

At baseline, all patients had hypokalemia (serum potassium <3.5 mmol/L). At 4W, 47 % (7/15) of patients achieved normal serum potassium without supplementation. Serum potassium levels significantly increased at the 2W, 4W, and 8W follow-ups compared to baseline (all p < 0.05). SBP significantly decreased at the 4W and 8W follow-ups (all p < 0.05), while DBP showed no significant changes. Increases in serum creatinine and decreases in eGFR were observed, particularly in patients with PA and chronic kidney disease (CKD), although these changes were not statistically significant. No instances of hyperkalemia or unexpected safety concerns were reported.

Conclusion

Finerenone effectively increased serum potassium levels and reduced SBP in PA, demonstrating its potential as a promising treatment option.

查看原文本刊更多论文

芬烯酮治疗原发性醛固酮增多症的疗效和安全性：一项前瞻性临床研究。

目的：本研究旨在评价芬烯酮治疗原发性醛固酮增多症（PA）的安全性和有效性。方法：共纳入15例PA患者。主要终点是在4周（4W）随访期间，在不补充钾的情况下达到正常血钾水平的患者比例。次要终点包括血清钾、24小时尿钾、收缩压（SBP）和舒张压（DBP）的变化。随访期间还评估了血清肌酐、肾小球滤过率（eGFR）和高钾血症的发生率。结果：基线时，所有患者均出现低钾血症（血钾）。结论：非那烯酮可有效提高PA患者的血钾水平，降低收缩压，显示其作为一种有前景的治疗选择的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & Metabolic Syndrome-Clinical Research & Reviews ENDOCRINOLOGY & METABOLISM-

CiteScore

22.90

自引率

2.00%

发文量

248

审稿时长

51 days

期刊介绍： Diabetes and Metabolic Syndrome: Clinical Research and Reviews is the official journal of DiabetesIndia. It aims to provide a global platform for healthcare professionals, diabetes educators, and other stakeholders to submit their research on diabetes care. Types of Publications: Diabetes and Metabolic Syndrome: Clinical Research and Reviews publishes peer-reviewed original articles, reviews, short communications, case reports, letters to the Editor, and expert comments. Reviews and mini-reviews are particularly welcomed for areas within endocrinology undergoing rapid changes.